NCT03434769 2026-02-27AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin LymphomaCase Comprehensive Cancer CenterPhase 1 Active not recruiting31 enrolled
NCT03277729 2026-01-05A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasFred Hutchinson Cancer CenterPhase 1/2 Active not recruiting53 enrolled 11 charts